Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Current Deferred Revenue (2024 - 2025)

Prelude Therapeutics' Current Deferred Revenue history spans 2 years, with the latest figure at $33.7 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue changed N/A year-over-year to $33.7 million; the TTM value through Dec 2025 reached $33.7 million, changed N/A, while the annual FY2025 figure was $33.7 million, N/A changed from the prior year.
  • Current Deferred Revenue for Q4 2025 was $33.7 million at Prelude Therapeutics, up from $3.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $33.7 million in Q4 2025 and bottomed at $3.0 million in Q2 2024.